Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

Thumbnail

FDA approves canagliflozin to treat diabetic kidney disease

The FDA approved canagliflozin Sept. 30 to reduce the risk of end-stage kidney disease, worsening kidney function, CV death and hospitalization for heart failure in adults with type 2 diabetes and diabetic nephropathy.

Thumbnail

New guideline supports consumption of red, processed meats

A panel of 14 international scientists published a nutritional guideline in the Annals of Internal Medicine this month suggesting adults continue consuming both red meat and processed meats, basing the recommendation on a mega-review that found few adverse health effects with either product.

Thumbnail

Higher-dose statins raise risk for osteoporosis

The higher the dosage of cholesterol-lowering statins, the greater a patient’s risk of developing osteoporosis, according to work published in the Annals of Rheumatic Diseases.

Thumbnail

FDA expands losartan recall—again

Torrent Pharmaceuticals Limited is the latest drug company to issue a recall of losartan potassium, a popular blood pressure drug that’s been under scrutiny for more than a year for containing probable human carcinogens.

Treating hypertension could slow cognitive decline

Research presented at the American Heart Association’s Hypertension 2019 Scientific Sessions this month suggests having high blood pressure speeds up cognitive decline in middle-aged and older adults—but treating the condition can reverse that possibility.

Thumbnail

At-home BP tests more accurate for black patients

Research out of UT Southwestern Medical Center in Dallas suggests at-home blood pressure monitoring is a more accurate approach to CV risk prediction in black patients.

Thumbnail

NLA endorses icosapent ethyl for use in high-risk patients

The National Lipid Association has issued a position statement recommending the use of icosapent ethyl for treating patients with atherosclerotic CVD or type 2 diabetes, rooting its endorsement in the positive results of the REDUCE-IT study.

Thumbnail

Apple launches a new heart study

Apple announced the initiation of three new large-scale medical studies, including one focused on women’s health, one focused on hearing and one focused on cardiovascular health and movement.